Bradley T. Christian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bradley T. Christian has a total of 255 co-authors. Here are the top co-authors by number of shared publications:
- Sterling C. Johnson
Wisconsin Alzheimer’s Disease Research Center, School of Medicine and Public Health, University of Wisconsin, Madison, USA
8 shared publications - Tobey James Betthauser
University of Wisconsin‐Madison School of Medicine and Public Health, Madison, WI USA
7 shared publications - Karly Alex Cody
Department of Neurology and Neurological Sciences Stanford University Stanford California USA
4 shared publications - Benjamin L. Handen
Department of Psychiatry, University of Pittsburgh, Thomas Detre Hall, 3811 O'Hara Street, Pittsburgh, PA 15213, USA
3 shared publications - Henrik Zetterberg
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden
3 shared publications - Kaj Blennow
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (7) , 1468-1481
Spatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts.
This longitudinal study including four independent cohorts assessed the spatiotemporal dynamics of tau extent and load changes in Alzheimer's disease using tau positron emission tomography data from 2,459 participants, including 898 followed for up to 7 years. Regional standardized uptake value ratios indexed tau load, whereas the spatial extent of tauopathy (SEOT) (proportion of abnormal voxels) measured tau extent. We observed burden-dependent longitudinal dynamics of tau progression: SEOT showed greater sensitivity to increases over time in regions with low baseline tau burden, whereas the standardized uptake value ratio was more informative for tracking accumulation once regional burden was established. This pattern was consistent across Braak regions and cohorts and was reflected in differential associations with other Alzheimer's disease severity markers. These findings refine models of tau propagation by suggesting that tau positron emission tomography changes may be differentially captured by extent-based and load-based metrics at different stages of disease progression, highlighting SEOT as a promising surrogate outcome for trials.
- 14 July 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (7) , 1468-1481
Open AccessSpatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts.
This longitudinal study including four independent cohorts assessed the spatiotemporal dynamics of tau extent and load changes in Alzheimer's disease using tau positron emission tomography data from 2,459 participants, including 898 followed for up to 7 years. Regional standardized uptake value ratios indexed tau load, whereas the spatial extent of tauopathy (SEOT) (proportion of abnormal voxels) measured tau extent. We observed burden-dependent longitudinal dynamics of tau progression: SEOT showed greater sensitivity to increases over time in regions with low baseline tau burden, whereas the standardized uptake value ratio was more informative for tracking accumulation once regional burden was established. This pattern was consistent across Braak regions and cohorts and was reflected in differential associations with other Alzheimer's disease severity markers. These findings refine models of tau propagation by suggesting that tau positron emission tomography changes may be differentially captured by extent-based and load-based metrics at different stages of disease progression, highlighting SEOT as a promising surrogate outcome for trials.
- Open Access
Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome
Objective: Adults with Down syndrome (DS) often show elevated systemic inflammation, but the association with obesity, aging, and Alzheimer's disease (AD) pathology is not well understood. Methods: Data were drawn from 188 nondemented adults with DS participating in the Alzheimer Biomarkers Consortium‐DS (ABC‐DS). Participants completed clinical assessments, blood draws, and neuroimaging. Plasma biomarkers included indicators of general, pro‐, and anti‐inflammation. Mixed linear models tested associations between BMI, age, PET‐measured amyloid burden, and inflammatory biomarkers, adjusting for sex, trisomy type, and collection site. False discovery rate correction was applied. Results: The majority of the participants met criteria for obesity. Higher BMI was significantly associated with elevated levels of CRP, IL‐6, TNF‐α, B2M, IL‐18, and slCAM‐1 ( p < 0.05). Older age was significantly associated with higher B2M ( β = 1.22e + 05, p < 0.001). Amyloid burden was positively associated with IL‐6 ( β = 0.005, p = 0.037). Conclusions: Obesity, aging, and amyloid burden relate to systemic inflammation in adults with DS. Obesity showed the strongest and most consistent associations, emphasizing the value of regular monitoring and weight management strategies to help reduce inflammation. Aging and early amyloid accumulation showed more limited links with systemic inflammation; future work should examine whether these processes are more closely related to biomarkers of neuroinflammation as AD progresses.
Open AccessInflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome
Objective: Adults with Down syndrome (DS) often show elevated systemic inflammation, but the association with obesity, aging, and Alzheimer's disease (AD) pathology is not well understood. Methods: Data were drawn from 188 nondemented adults with DS participating in the Alzheimer Biomarkers Consortium‐DS (ABC‐DS). Participants completed clinical assessments, blood draws, and neuroimaging. Plasma biomarkers included indicators of general, pro‐, and anti‐inflammation. Mixed linear models tested associations between BMI, age, PET‐measured amyloid burden, and inflammatory biomarkers, adjusting for sex, trisomy type, and collection site. False discovery rate correction was applied. Results: The majority of the participants met criteria for obesity. Higher BMI was significantly associated with elevated levels of CRP, IL‐6, TNF‐α, B2M, IL‐18, and slCAM‐1 ( p < 0.05). Older age was significantly associated with higher B2M ( β = 1.22e + 05, p < 0.001). Amyloid burden was positively associated with IL‐6 ( β = 0.005, p = 0.037). Conclusions: Obesity, aging, and amyloid burden relate to systemic inflammation in adults with DS. Obesity showed the strongest and most consistent associations, emphasizing the value of regular monitoring and weight management strategies to help reduce inflammation. Aging and early amyloid accumulation showed more limited links with systemic inflammation; future work should examine whether these processes are more closely related to biomarkers of neuroinflammation as AD progresses.
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e214938
Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome
Background and ObjectivesThere is a paucity of research on the role of circadian rhythm disruption in Alzheimer disease (AD)-related cognitive impairments in adults with Down syndrome (DS). The aim...
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e214938
Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome
Background and ObjectivesThere is a paucity of research on the role of circadian rhythm disruption in Alzheimer disease (AD)-related cognitive impairments in adults with Down syndrome (DS). The aim...
- Open Access
- 29 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
CSF total tau as a proxy of synaptic degeneration
Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer’s disease (AD). However, previous studies show that CSF t-tau correlates strongly with synaptic dysfunction/degeneration biomarkers like neurogranin (Ng) and synaptosomal-associated protein 25 (SNAP25). Here, we compare the association between CSF t-tau and synaptic degeneration and axonal/neuronal degeneration biomarkers in cognitively unimpaired and impaired groups from two independent cohorts. We observe a stronger correlation between CSF t-tau and synaptic biomarkers than neurodegeneration biomarkers in both groups. Synaptic biomarkers explain a greater proportion of variance in CSF t-tau levels compared to neurodegeneration biomarkers. Notably, CSF t-tau levels are elevated in individuals with abnormalities only in synaptic biomarkers, but not in individuals with abnormalities only in neurodegeneration biomarkers. Our findings suggest that CSF t-tau is a closer proxy for synaptic degeneration than for axonal/neuronal degeneration.
- 29 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessCSF total tau as a proxy of synaptic degeneration
Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer’s disease (AD). However, previous studies show that CSF t-tau correlates strongly with synaptic dysfunction/degeneration biomarkers like neurogranin (Ng) and synaptosomal-associated protein 25 (SNAP25). Here, we compare the association between CSF t-tau and synaptic degeneration and axonal/neuronal degeneration biomarkers in cognitively unimpaired and impaired groups from two independent cohorts. We observe a stronger correlation between CSF t-tau and synaptic biomarkers than neurodegeneration biomarkers in both groups. Synaptic biomarkers explain a greater proportion of variance in CSF t-tau levels compared to neurodegeneration biomarkers. Notably, CSF t-tau levels are elevated in individuals with abnormalities only in synaptic biomarkers, but not in individuals with abnormalities only in neurodegeneration biomarkers. Our findings suggest that CSF t-tau is a closer proxy for synaptic degeneration than for axonal/neuronal degeneration.
- Top Cited PapersOpen Access
- 16 July 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (8) , 1610-1621
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Tau positron emission tomography (PET) imaging allows in vivo detection of tau proteinopathy in Alzheimer’s disease, which is associated with neurodegeneration and cognitive decline. Understanding how demographic, clinical and genetic factors relate to tau PET positivity will facilitate its use for clinical practice and research. Here we conducted an analysis of 42 cohorts worldwide (N = 12,048), including 7,394 cognitively unimpaired (CU) participants, 2,177 participants with mild cognitive impairment (MCI) and 2,477 participants with dementia. We found that from age 60 years to 80 years, tau PET positivity in a temporal composite region increased from 1.1% to 4.4% among CU amyloid-β (Aβ)-negative participants and from 17.4% to 22.2% among CU Aβ-positive participants. Across the same age span, tau PET positivity decreased from 68.0% to 52.9% in participants with MCI and from 91.5% to 74.6% in participants with dementia. Age, Aβ status, APOE ε4 carriership and female sex were all associated with a higher prevalence of tau PET positivity across groups. APOE ε4 carriership in CU individuals lowered the age at onset of both Aβ positivity and tau positivity by decades. Finally, we replicated these associations in an independent autopsy dataset (N = 5,072 from 3 cohorts).
- 16 July 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (8) , 1610-1621
Top Cited PapersOpen AccessTau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Tau positron emission tomography (PET) imaging allows in vivo detection of tau proteinopathy in Alzheimer’s disease, which is associated with neurodegeneration and cognitive decline. Understanding how demographic, clinical and genetic factors relate to tau PET positivity will facilitate its use for clinical practice and research. Here we conducted an analysis of 42 cohorts worldwide (N = 12,048), including 7,394 cognitively unimpaired (CU) participants, 2,177 participants with mild cognitive impairment (MCI) and 2,477 participants with dementia. We found that from age 60 years to 80 years, tau PET positivity in a temporal composite region increased from 1.1% to 4.4% among CU amyloid-β (Aβ)-negative participants and from 17.4% to 22.2% among CU Aβ-positive participants. Across the same age span, tau PET positivity decreased from 68.0% to 52.9% in participants with MCI and from 91.5% to 74.6% in participants with dementia. Age, Aβ status, APOE ε4 carriership and female sex were all associated with a higher prevalence of tau PET positivity across groups. APOE ε4 carriership in CU individuals lowered the age at onset of both Aβ positivity and tau positivity by decades. Finally, we replicated these associations in an independent autopsy dataset (N = 5,072 from 3 cohorts).
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
Effects of biomarker timing on preclinical cognitive trajectories and tau PET accumulation
Background: The timing of AD biomarker positivity may be important for defining optimal anti‐amyloid therapy windows for secondary prevention. This work characterizes the AD biological cascade and investigates biomarker onset timing and associations of timing with preclinical cognitive decline and tau PET accumulation using data from the Wisconsin Registry for Alzheimer’s Prevention (WRAP).Method: WRAP participants (N = 172; mean(SD) age at last plasma = 69.4(6.6) years; 159 unimpaired, 9 MCI, 3 dementia, 1 impaired non‐AD) with available plasma pTau217, amyloid PET, and longitudinal cognitive assessments were included. Plasma pTau217 was quantified using an immunoassay on the Meso Scale Discovery platform (Lilly Research Laboratories). Amyloid burden was quantified using cortical 11C‐PiB DVR (cerebellum GM reference region). Positivity thresholds were defined using group‐based trajectory modeling applied to participants with longitudinal (≥2) biomarker observations (Ptau217, n = 162; PiB, n = 155). Sampled iterative local approximation (SILA) was used to model longitudinal PiB and pTau217 trajectories and estimate biomarker onset ages. Biomarker timing groups were defined as: PiB(‐)/pTau217(‐); coincident (PiB(+) and pTau217(+) onsets within 2 years of each other); PiB(+) first; or pTau217(+) first. We used a linear mixed effects model (random intercept and age‐related slope; unstructured covariance) to investigate the impact of biomarker timing group on cognitive decline measured by a three‐test Preclinical Alzheimer’s Cognitive Composite (PACC‐3). In a subset with tau PET (n = 120), we assessed regional tau burden (18F‐MK‐6240 SUVRs; 70‐90min, inferior cerebellar GM reference region) relative to plasma pTau217(+) and PiB(+) timing.Result: In the PiB(+)/pTau217(+) subset (n = 60; 35%), PiB(+) onset generally preceded pTau217(+), but with considerable heterogeneity in this timing (Figure 1A‐H). Older age at PiB(+) onset was associated with shorter time to pTau217(+) onset (Figure 1G‐H). In PACC‐3 analyses, post‐hoc analyses of the significant biomarker timing group*age interaction showed fastest decline in the pTau217(+) first group (Figure 2). Both PiB(+) and pTau217(+) durations predicted MK‐6240 accumulation; ∆AICc indicated better fit with pTau217(+) time (Figure 3).Conclusion: In this mostly preclinical sample, the timing of PiB(+) and plasma pTau217(+) were differentially associated with cognitive decline and tau PET accumulation. These preliminary findings suggest secondary AD prevention with anti‐amyloid therapy may be most beneficial before pTau217 onset.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
Open AccessEffects of biomarker timing on preclinical cognitive trajectories and tau PET accumulation
Background: The timing of AD biomarker positivity may be important for defining optimal anti‐amyloid therapy windows for secondary prevention. This work characterizes the AD biological cascade and investigates biomarker onset timing and associations of timing with preclinical cognitive decline and tau PET accumulation using data from the Wisconsin Registry for Alzheimer’s Prevention (WRAP).Method: WRAP participants (N = 172; mean(SD) age at last plasma = 69.4(6.6) years; 159 unimpaired, 9 MCI, 3 dementia, 1 impaired non‐AD) with available plasma pTau217, amyloid PET, and longitudinal cognitive assessments were included. Plasma pTau217 was quantified using an immunoassay on the Meso Scale Discovery platform (Lilly Research Laboratories). Amyloid burden was quantified using cortical 11C‐PiB DVR (cerebellum GM reference region). Positivity thresholds were defined using group‐based trajectory modeling applied to participants with longitudinal (≥2) biomarker observations (Ptau217, n = 162; PiB, n = 155). Sampled iterative local approximation (SILA) was used to model longitudinal PiB and pTau217 trajectories and estimate biomarker onset ages. Biomarker timing groups were defined as: PiB(‐)/pTau217(‐); coincident (PiB(+) and pTau217(+) onsets within 2 years of each other); PiB(+) first; or pTau217(+) first. We used a linear mixed effects model (random intercept and age‐related slope; unstructured covariance) to investigate the impact of biomarker timing group on cognitive decline measured by a three‐test Preclinical Alzheimer’s Cognitive Composite (PACC‐3). In a subset with tau PET (n = 120), we assessed regional tau burden (18F‐MK‐6240 SUVRs; 70‐90min, inferior cerebellar GM reference region) relative to plasma pTau217(+) and PiB(+) timing.Result: In the PiB(+)/pTau217(+) subset (n = 60; 35%), PiB(+) onset generally preceded pTau217(+), but with considerable heterogeneity in this timing (Figure 1A‐H). Older age at PiB(+) onset was associated with shorter time to pTau217(+) onset (Figure 1G‐H). In PACC‐3 analyses, post‐hoc analyses of the significant biomarker timing group*age interaction showed fastest decline in the pTau217(+) first group (Figure 2). Both PiB(+) and pTau217(+) durations predicted MK‐6240 accumulation; ∆AICc indicated better fit with pTau217(+) time (Figure 3).Conclusion: In this mostly preclinical sample, the timing of PiB(+) and plasma pTau217(+) were differentially associated with cognitive decline and tau PET accumulation. These preliminary findings suggest secondary AD prevention with anti‐amyloid therapy may be most beneficial before pTau217 onset.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Using Different Time Operationalizations To Investigate Relationships Among Amyloid PET, White Matter Hyperintensities, And Cognition In A Cognitively Unimpaired Sample
Background: Amyloid‐PET and white matter hyperintensities (WMH) associations in older adults have variously been interpreted as separate or dependent processes. In this study, we examine evidence for a temporal relationship between amyloid‐PET and WMH and investigate how both contribute to cognitive decline in a baseline cognitively unimpaired (CU) sample.Method: We analyzed longitudinal WMH and PACC3 cognition in n = 240 Wisconsin Registry for Alzheimer’s Prevention participants who were CU at cognitive baseline with ≥1 amyloid‐PET and T2‐FLAIR scan. Amyloid burden was assessed using [C‐11]Pittsburgh Compound B (PiB) PET and a multi‐ROI DVR value; DVR>1.19 = PiB+. WMH lesion volume was segmented and summed by the Lesion Segmentation Tool (LST) version 1.2.3 in SPM12 from T1‐weighted and T2‐weighted FLAIR scans; TIV‐adjusted WMH >2.06 = WMH+. Sampled iterative local approximation (SILA) modeling aligned biomarker levels to positivity duration scale (years = 0 at biomarker+ threshold). To investigate how amyloid burden relates to WMH trajectories, time at each WMH scan was operationalized four ways: age, ∼WMH+ duration, years_since_baseline_scan, and ∼PiB+ duration. We compared model fits and interaction effects for the various PiB status*time interactions (mixed effects models; retaining significant quadratic time terms; random slopes and intercepts). We also examined whether PACC3 age‐related trajectories differed by PiB/WMH +/‐ groups (at last scan).Result: More women were WMH+ and APOE4 was more common among PiB+ (see also Table1). Significant interactions using age or years_since_baseline_scan suggested slightly faster WMH accumulation in PiB+ vs PiB‐ at older ages. In parallel models, WMH+ duration*PiB status and PiB+ duration*PiB status did not show differences between PiB+ and PiB‐ WMH trajectories. Time operationalized as WMH+ duration yielded the best fitting model (see Table2 and Fig1A‐D). PACC3 decline was fastest in the PiB+/WMH+ group, followed by PiB+/WMH‐ (Fig1E). PiB+ was more common than WMH+ and tended to precede it when both were present (Table1; Fig1F).Conclusion: In this baseline CU sample, WMH+ was less common and occurred later in life, on average, than PiB+. Associations between amyloid burden and WMH trajectories were driven by older ages, suggesting potential unidentified age‐related mediators in this relationship. Presence of both amyloid and WMH was associated with fastest preclinical cognitive decline.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessUsing Different Time Operationalizations To Investigate Relationships Among Amyloid PET, White Matter Hyperintensities, And Cognition In A Cognitively Unimpaired Sample
Background: Amyloid‐PET and white matter hyperintensities (WMH) associations in older adults have variously been interpreted as separate or dependent processes. In this study, we examine evidence for a temporal relationship between amyloid‐PET and WMH and investigate how both contribute to cognitive decline in a baseline cognitively unimpaired (CU) sample.Method: We analyzed longitudinal WMH and PACC3 cognition in n = 240 Wisconsin Registry for Alzheimer’s Prevention participants who were CU at cognitive baseline with ≥1 amyloid‐PET and T2‐FLAIR scan. Amyloid burden was assessed using [C‐11]Pittsburgh Compound B (PiB) PET and a multi‐ROI DVR value; DVR>1.19 = PiB+. WMH lesion volume was segmented and summed by the Lesion Segmentation Tool (LST) version 1.2.3 in SPM12 from T1‐weighted and T2‐weighted FLAIR scans; TIV‐adjusted WMH >2.06 = WMH+. Sampled iterative local approximation (SILA) modeling aligned biomarker levels to positivity duration scale (years = 0 at biomarker+ threshold). To investigate how amyloid burden relates to WMH trajectories, time at each WMH scan was operationalized four ways: age, ∼WMH+ duration, years_since_baseline_scan, and ∼PiB+ duration. We compared model fits and interaction effects for the various PiB status*time interactions (mixed effects models; retaining significant quadratic time terms; random slopes and intercepts). We also examined whether PACC3 age‐related trajectories differed by PiB/WMH +/‐ groups (at last scan).Result: More women were WMH+ and APOE4 was more common among PiB+ (see also Table1). Significant interactions using age or years_since_baseline_scan suggested slightly faster WMH accumulation in PiB+ vs PiB‐ at older ages. In parallel models, WMH+ duration*PiB status and PiB+ duration*PiB status did not show differences between PiB+ and PiB‐ WMH trajectories. Time operationalized as WMH+ duration yielded the best fitting model (see Table2 and Fig1A‐D). PACC3 decline was fastest in the PiB+/WMH+ group, followed by PiB+/WMH‐ (Fig1E). PiB+ was more common than WMH+ and tended to precede it when both were present (Table1; Fig1F).Conclusion: In this baseline CU sample, WMH+ was less common and occurred later in life, on average, than PiB+. Associations between amyloid burden and WMH trajectories were driven by older ages, suggesting potential unidentified age‐related mediators in this relationship. Presence of both amyloid and WMH was associated with fastest preclinical cognitive decline.
- Open Access
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Effects of biomarker timing on preclinical cognitive trajectories and tau PET accumulation
Background: The timing of AD biomarker positivity may be important for defining optimal anti‐amyloid therapy windows for secondary prevention. This work characterizes the AD biological cascade and investigates biomarker onset timing and associations of timing with preclinical cognitive decline and tau PET accumulation using data from the Wisconsin Registry for Alzheimer’s Prevention (WRAP).Method: WRAP participants (N = 172; mean(SD) age at last plasma = 69.4(6.6) years; 159 unimpaired, 9 MCI, 3 dementia, 1 impaired non‐AD) with available plasma pTau217, amyloid PET, and longitudinal cognitive assessments were included. Plasma pTau217 was quantified using an immunoassay on the Meso Scale Discovery platform (Lilly Research Laboratories). Amyloid burden was quantified using cortical 11C‐PiB DVR (cerebellum GM reference region). Positivity thresholds were defined using group‐based trajectory modeling applied to participants with longitudinal (≥2) biomarker observations (Ptau217, n = 162; PiB, n = 155). Sampled iterative local approximation (SILA) was used to model longitudinal PiB and pTau217 trajectories and estimate biomarker onset ages. Biomarker timing groups were defined as: PiB(‐)/pTau217(‐); coincident (PiB(+) and pTau217(+) onsets within 2 years of each other); PiB(+) first; or pTau217(+) first. We used a linear mixed effects model (random intercept and age‐related slope; unstructured covariance) to investigate the impact of biomarker timing group on cognitive decline measured by a three‐test Preclinical Alzheimer’s Cognitive Composite (PACC‐3). In a subset with tau PET (n = 120), we assessed regional tau burden (18F‐MK‐6240 SUVRs; 70‐90min, inferior cerebellar GM reference region) relative to plasma pTau217(+) and PiB(+) timing.Result: In the PiB(+)/pTau217(+) subset (n = 60; 35%), PiB(+) onset generally preceded pTau217(+), but with considerable heterogeneity in this timing (Figure 1A‐H). Older age at PiB(+) onset was associated with shorter time to pTau217(+) onset (Figure 1G‐H). In PACC‐3 analyses, post‐hoc analyses of the significant biomarker timing group*age interaction showed fastest decline in the pTau217(+) first group (Figure 2). Both PiB(+) and pTau217(+) durations predicted MK‐6240 accumulation; ∆AICc indicated better fit with pTau217(+) time (Figure 3).Conclusion: In this mostly preclinical sample, the timing of PiB(+) and plasma pTau217(+) were differentially associated with cognitive decline and tau PET accumulation. These preliminary findings suggest secondary AD prevention with anti‐amyloid therapy may be most beneficial before pTau217 onset.
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Open AccessEffects of biomarker timing on preclinical cognitive trajectories and tau PET accumulation
Background: The timing of AD biomarker positivity may be important for defining optimal anti‐amyloid therapy windows for secondary prevention. This work characterizes the AD biological cascade and investigates biomarker onset timing and associations of timing with preclinical cognitive decline and tau PET accumulation using data from the Wisconsin Registry for Alzheimer’s Prevention (WRAP).Method: WRAP participants (N = 172; mean(SD) age at last plasma = 69.4(6.6) years; 159 unimpaired, 9 MCI, 3 dementia, 1 impaired non‐AD) with available plasma pTau217, amyloid PET, and longitudinal cognitive assessments were included. Plasma pTau217 was quantified using an immunoassay on the Meso Scale Discovery platform (Lilly Research Laboratories). Amyloid burden was quantified using cortical 11C‐PiB DVR (cerebellum GM reference region). Positivity thresholds were defined using group‐based trajectory modeling applied to participants with longitudinal (≥2) biomarker observations (Ptau217, n = 162; PiB, n = 155). Sampled iterative local approximation (SILA) was used to model longitudinal PiB and pTau217 trajectories and estimate biomarker onset ages. Biomarker timing groups were defined as: PiB(‐)/pTau217(‐); coincident (PiB(+) and pTau217(+) onsets within 2 years of each other); PiB(+) first; or pTau217(+) first. We used a linear mixed effects model (random intercept and age‐related slope; unstructured covariance) to investigate the impact of biomarker timing group on cognitive decline measured by a three‐test Preclinical Alzheimer’s Cognitive Composite (PACC‐3). In a subset with tau PET (n = 120), we assessed regional tau burden (18F‐MK‐6240 SUVRs; 70‐90min, inferior cerebellar GM reference region) relative to plasma pTau217(+) and PiB(+) timing.Result: In the PiB(+)/pTau217(+) subset (n = 60; 35%), PiB(+) onset generally preceded pTau217(+), but with considerable heterogeneity in this timing (Figure 1A‐H). Older age at PiB(+) onset was associated with shorter time to pTau217(+) onset (Figure 1G‐H). In PACC‐3 analyses, post‐hoc analyses of the significant biomarker timing group*age interaction showed fastest decline in the pTau217(+) first group (Figure 2). Both PiB(+) and pTau217(+) durations predicted MK‐6240 accumulation; ∆AICc indicated better fit with pTau217(+) time (Figure 3).Conclusion: In this mostly preclinical sample, the timing of PiB(+) and plasma pTau217(+) were differentially associated with cognitive decline and tau PET accumulation. These preliminary findings suggest secondary AD prevention with anti‐amyloid therapy may be most beneficial before pTau217 onset.